Integral Health Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Integral Health Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$12.6M	–	98
2026 Q1	$12.6M	Sell	150,000 -125,000	-45%	-$7.24M	0.6%	44
2025 Q4	$11.3M	Buy	275,000 +125,000	+83%	+$4.85M	0.56%	56
2025 Q3	$5.9M	Buy	+150,000	New	+$3.83M	0.4%	67
2023 Q1	–	Sell	-26,000	Closed	-$164K	–	77
2022 Q4	$164K	Buy	26,000 +2,437	+10%	+$43.1K	0.03%	61
2022 Q3	$532K	Buy	23,563 +3,046	+15%	+$83.4K	0.1%	64
2022 Q2	$394K	Buy	20,517 +7,954	+63%	+$197K	0.08%	64
2022 Q1	$583K	Buy	12,563 +6,938	+123%	+$379K	0.15%	68
2021 Q4	$399K	Hold	5,625	–	–	0.11%	69
2021 Q3	$655K	Buy	5,625 +937	+20%	+$109K	0.19%	67
2021 Q2	$734K	Buy	4,688 +625	+15%	+$115K	0.2%	67
2021 Q1	$770K	Buy	+4,063	New	+$684K	0.22%	64

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Integral Health Asset Management's DNTH Position: Q2 2026 in Review

Integral Health Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 150,000 shares — an estimated $12.6M sold.

Integral Health Asset Management first reported a position in DNTH in Q1 2021 and held it in 11 quarters. The position peaked at $12.6M in Q1 2026. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Integral Health Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
Integral Health Asset Management sold 150,000 Dianthus Therapeutics shares in Q2 2026, an estimated $12.6M.
Integral Health Asset Management first reported a position in Dianthus Therapeutics in Q1 2021 and held it in 11 quarters.
Integral Health Asset Management's Dianthus Therapeutics position peaked at $12.6M in Q1 2026.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.